ParsabivActive Ingredient(s): Etelcalcetide
FDA Approved: * February 7, 2017
Pharm Company: * KAI PHARMS INC
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.&am... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.